{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:33:36Z","timestamp":1791290016942,"version":"4.3.0"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T00:00:00Z","timestamp":1438560000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F 3513-B20"],"award-info":[{"award-number":["F 3513-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I1609-B24"],"award-info":[{"award-number":["I1609-B24"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P24894-B24"],"award-info":[{"award-number":["P24894-B24"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The adenosine triphosphate-binding cassette transporter P-glycoprotein (ABCB1\/Abcb1a) restricts at the blood\u2013brain barrier (BBB) brain distribution of many drugs. ABCB1 may be involved in drug\u2013drug interactions (DDIs) at the BBB, which may lead to changes in brain distribution and central nervous system side effects of drugs. Positron emission tomography (PET) with the ABCB1 substrates (R)-[11C]verapamil and [11C]-N-desmethyl-loperamide and the ABCB1 inhibitor tariquidar has allowed direct comparison of ABCB1-mediated DDIs at the rodent and human BBB. In this work we evaluated different factors which could influence the magnitude of the interaction between tariquidar and (R)-[11C]verapamil or [11C]-N-desmethyl-loperamide at the BBB and thereby contribute to previously observed species differences between rodents and humans. We performed in vitro transport experiments with [3H]verapamil and [3H]-N-desmethyl-loperamide in ABCB1 and Abcb1a overexpressing cell lines. Moreover we conducted in vivo PET experiments and biodistribution studies with (R)-[11C]verapamil and [11C]-N-desmethyl-loperamide in wild-type mice without and with tariquidar pretreatment and in homozygous Abcb1a\/1b(\u2212\/\u2212) and heterozygous Abcb1a\/1b(+\/\u2212) mice. We found no differences for in vitro transport of [3H]verapamil and [3H]-N-desmethyl-loperamide by ABCB1 and Abcb1a and its inhibition by tariquidar. [3H]-N-Desmethyl-loperamide was transported with a 5 to 9 times higher transport ratio than [3H]verapamil in ABCB1- and Abcb1a-transfected cells. In vivo, brain radioactivity concentrations were lower for [11C]-N-desmethyl-loperamide than for (R)-[11C]verapamil. Both radiotracers showed tariquidar dose dependent increases in brain distribution with tariquidar half-maximum inhibitory concentrations (IC50) of 1052 nM (95% confidence interval CI: 930\u20131189) for (R)-[11C]verapamil and 1329 nM (95% CI: 980\u20131801) for [11C]-N-desmethyl-loperamide. In homozygous Abcb1a\/1b(\u2212\/\u2212) mice brain radioactivity distribution was increased by 3.9- and 2.8-fold and in heterozygous Abcb1a\/1b(+\/\u2212) mice by 1.5- and 1.1-fold, for (R)-[11C]verapamil and [11C]-N-desmethyl-loperamide, respectively, as compared with wild-type mice. For both radiotracers radiolabeled metabolites were detected in plasma and brain. When brain and plasma radioactivity concentrations were corrected for radiolabeled metabolites, brain distribution of (R)-[11C]verapamil and [11C]-N-desmethyl-loperamide was increased in tariquidar (15 mg\/kg) treated animals by 14.1- and 18.3-fold, respectively, as compared with vehicle group. Isoflurane anesthesia altered [11C]-N-desmethyl-loperamide but not (R)-[11C]verapamil metabolism, and this had a direct effect on the magnitude of the increase in brain distribution following ABCB1 inhibition. Our data furthermore suggest that in the absence of ABCB1 function brain distribution of [11C]-N-desmethyl-loperamide but not (R)-[11C]verapamil may depend on cerebral blood flow. In conclusion, we have identified a number of important factors, i.e., substrate affinity to ABCB1, brain uptake of radiolabeled metabolites, anesthesia, and cerebral blood flow, which can directly influence the magnitude of ABCB1-mediated DDIs at the BBB and should therefore be taken into consideration when interpreting PET results.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.5b00168","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T21:23:38Z","timestamp":1437600218000},"page":"3214-3225","source":"Crossref","is-referenced-by-count":49,"title":["Factors Governing P-Glycoprotein-Mediated Drug\u2013Drug Interactions at the Blood\u2013Brain Barrier Measured with Positron Emission Tomography"],"prefix":"10.1021","volume":"12","author":[{"given":"Thomas","family":"Wanek","sequence":"first","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Ro\u0308mermann","sequence":"additional","affiliation":[{"name":"University of Veterinary Medicine Hannover , , ,","place":["Hannover, Germany"]},{"name":"Medical University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Mairinger","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Stanek","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]},{"name":"Medical University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sauberer","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Filip","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Traxl","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kuntner","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Pahnke","sequence":"additional","affiliation":[{"name":"University of Oslo (UiO) and Oslo University Hospital (OUS) , , ,","place":["Oslo, Norway"]},{"name":"University of Lu\u0308beck , , ,","place":["Lu\u0308beck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bauer","sequence":"additional","affiliation":[{"name":"University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Erker","sequence":"additional","affiliation":[{"name":"University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Lo\u0308scher","sequence":"additional","affiliation":[{"name":"University of Veterinary Medicine Hannover , , ,","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mu\u0308ller","sequence":"additional","affiliation":[{"name":"Medical University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langer","sequence":"additional","affiliation":[{"name":"AIT Austrian Institute of Technology GmbH , , ,","place":["Seibersdorf, Austria"]},{"name":"Medical University of Vienna , , ,","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2015,7,22]]},"reference":[{"key":"2026090221451685500_cit1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation\nof efflux transport at the human blood-brain barrier is unlikely:\nthe ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin. Pharmacol.\nTher."},{"key":"2026090221451685500_cit2","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1172\/JCI118214","article-title":"Absence of\nthe mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics\nof dexamethasone, digoxin, and cyclosporin A","volume":"96","author":"Schinkel","year":"1995","journal-title":"J. Clin. Invest."},{"key":"2026090221451685500_cit3","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein\nin the blood-brain barrier of mice influences the brain penetration\nand pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2026090221451685500_cit4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse\nmdr1a P-glycoprotein gene leads to a deficiency in the blood-brain\nbarrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"2026090221451685500_cit5","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/jps.20658","article-title":"Development\nof a P-glycoprotein knockout model in rodents to define species differences\nin its functional effect at the blood-brain barrier","volume":"95","author":"Cutler","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"2026090221451685500_cit6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15144-6","article-title":"Pharmacological inhibition of P-glycoprotein\ntransport enhances the distribution of HIV-1 protease inhibitors into\nbrain and testes","volume":"28","author":"Choo","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"2026090221451685500_cit7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1124\/jpet.105.099648","article-title":"Differential\nin vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes,\ntestes, and the blood-brain barrier","volume":"317","author":"Choo","year":"2006","journal-title":"J. Pharmacol.\nExp. Ther."},{"key":"2026090221451685500_cit8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2009.03.017","article-title":"Drug interactions at the blood-brain barrier: fact\nor fantasy?","volume":"123","author":"Eyal","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"2026090221451685500_cit9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1067\/mcp.2000.109156","article-title":"Increased drug delivery to the brain\nby P-glycoprotein inhibition","volume":"68","author":"Sadeque","year":"2000","journal-title":"Clin. Pharmacol.\nTher."},{"key":"2026090221451685500_cit10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/ALN.0b013e31818d8f28","article-title":"Tariquidar, a selective P-glycoprotein\ninhibitor, does not potentiate loperamide\u2019s opioid brain effects\nin humans despite full inhibition of lymphocyte P-glycoprotein","volume":"109","author":"Kurnik","year":"2008","journal-title":"Anesthesiology"},{"key":"2026090221451685500_cit11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/clpt.2014.70","article-title":"Using positron emission tomography\nto study transporter-mediated drug-drug interactions in tissues","volume":"96","author":"Wulkersdorfer","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090221451685500_cit12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.bjp.0701979","article-title":"Complete\nin vivo reversal of P-glycoprotein pump function in the blood-brain\nbarrier visualized with positron emission tomography","volume":"124","author":"Hendrikse","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"2026090221451685500_cit13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","article-title":"Imaging P-glycoprotein\ntransport activity at the human blood-brain barrier with positron\nemission tomography","volume":"77","author":"Sasongko","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090221451685500_cit14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2967\/jnumed.108.059162","article-title":"Imaging\nof cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans","volume":"50","author":"Muzi","year":"2009","journal-title":"J. Nucl. Med."},{"key":"2026090221451685500_cit15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0969-8051(03)00078-7","article-title":"(R)- and (S)-[11C]verapamil as PET-tracers for measuring\nP-glycoprotein function: in vitro and in vivo evaluation","volume":"30","author":"Luurtsema","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.jcbfm.9600349","article-title":"Evaluation of tracer kinetic models\nfor quantification of P-glycoprotein function using (R)-[11C]verapamil and PET","volume":"27","author":"Lubberink","year":"2007","journal-title":"J. Cereb.\nBlood Flow Metab."},{"key":"2026090221451685500_cit17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2967\/jnumed.109.063289","article-title":"A pilot study to assess\nthe efficacy of tariquidar to inhibit P-glycoprotein at the human\nblood-brain barrier with (R)-11C-verapamil\nand PET","volume":"50","author":"Wagner","year":"2009","journal-title":"J. Nucl. Med."},{"key":"2026090221451685500_cit18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/clpt.2011.217","article-title":"Pgp-mediated interaction between\n(R)-[11C]verapamil and tariquidar at the\nhuman blood-brain barrier: a comparison with rat data","volume":"91","author":"Bauer","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090221451685500_cit19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/jcbfm.2015.19","article-title":"Approaching complete\ninhibition of P-glycoprotein at the human blood-brain barrier: an\n(R)-[11C]verapamil PET study","volume":"35","author":"Bauer","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2026090221451685500_cit20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2967\/jnumed.109.070151","article-title":"P-glycoprotein function at the blood-brain\nbarrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide","volume":"51","author":"Kreisl","year":"2010","journal-title":"J. Nucl.\nMed."},{"key":"2026090221451685500_cit21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.114.146894","article-title":"Increased permeability-glycoprotein\ninhibition at the human blood-brain barrier can be safely achieved\nby performing PET during peak plasma concentrations of tariquidar","volume":"56","author":"Kreisl","year":"2015","journal-title":"J. Nucl. Med."},{"key":"2026090221451685500_cit22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump\ninhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2026090221451685500_cit23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1124\/jpet.105.097931","article-title":"Verapamil\nP-glycoprotein transport across the rat blood-brain barrier: cyclosporine,\na concentration inhibition analysis, and comparison with human data","volume":"317","author":"Hsiao","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026090221451685500_cit24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative\ntargeted absolute proteomics of human blood-brain barrier transporters\nand receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"key":"2026090221451685500_cit25","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1021\/jm800510m","article-title":"Synthesis and evaluation\nof [N-methyl-11C]N-desmethyl-loperamide as a new and improved\nPET radiotracer for imaging P-gp function","volume":"51","author":"Lazarova","year":"2008","journal-title":"J.\nMed. Chem."},{"key":"2026090221451685500_cit26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences\nin the transport of the antiepileptic drugs phenytoin, levetiracetam\nand carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"2026090221451685500_cit27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for\nhuman P-glycoprotein","volume":"55","author":"Luna-Torto\u0301s","year":"2008","journal-title":"Neuropharmacology"},{"key":"2026090221451685500_cit28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational\nuse of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026090221451685500_cit29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clpt.2005.04.011","article-title":"Influence of functional haplotypes\nin the drug transporter gene ABCB1 on central nervous system drug\ndistribution in humans","volume":"78","author":"Brunner","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"2026090221451685500_cit30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/jcbfm.1985.35","article-title":"Blood-brain barrier\ntransport of butanol and water relative to N-isopropyl-p-iodoamphetamine\nas the internal reference","volume":"5","author":"Pardridge","year":"1985","journal-title":"J. Cereb. Blood Flow\nMetab."},{"key":"2026090221451685500_cit31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1162\/153535003322556877","article-title":"AMIDE: a free software tool for multimodality medical\nimage analysis","volume":"2","author":"Loening","year":"2003","journal-title":"Mol. Imaging"},{"key":"2026090221451685500_cit32","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1021\/jm8013822","article-title":"Potent and selective inhibitors of breast cancer resistance\nprotein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator\ntariquidar","volume":"52","author":"Ku\u0308hnle","year":"2009","journal-title":"J. Med. Chem."},{"key":"2026090221451685500_cit33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.nucmedbio.2013.05.012","article-title":"(R)-[11C]verapamil is selectively transported by murine\nand human P-glycoprotein at the blood-brain barrier, and not by MRP1\nand BCRP","volume":"40","author":"Ro\u0308mermann","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1124\/dmd.109.031161","article-title":"N-desmethyl-loperamide is selective for P-glycoprotein\namong three ATP-binding cassette transporters at the blood-brain barrier","volume":"38","author":"Kannan","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"2026090221451685500_cit35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00259-009-1332-5","article-title":"Dose-response assessment of tariquidar and elacridar\nand regional quantification of P-glycoprotein inhibition at the rat\nblood-brain barrier using (R)-[11C]verapamil\nPET","volume":"37","author":"Kuntner","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026090221451685500_cit36","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1073\/pnas.1014641108","article-title":"Lysosomal trapping of a radiolabeled\nsubstrate of P-glycoprotein as a mechanism for signal amplification\nin PET","volume":"108","author":"Kannan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090221451685500_cit37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1124\/dmd.112.049148","article-title":"Tariquidar and elacridar\nare dose-dependently transported by p-glycoprotein and bcrp at the\nblood-brain barrier: a small-animal positron emission tomography and\nin vitro study","volume":"41","author":"Bankstahl","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"2026090221451685500_cit38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1124\/dmd.112.049577","article-title":"Retrospective analysis of P-glycoprotein-mediated\ndrug-drug interactions at the blood-brain barrier in humans","volume":"41","author":"Sugimoto","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"2026090221451685500_cit39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/taap.1997.8225","article-title":"Identification of a P-glycoprotein-deficient\nsubpopulation in the CF-1 mouse strain using a restriction fragment\nlength polymorphism","volume":"146","author":"Umbenhauer","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2026090221451685500_cit40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/jpet.113.205583","article-title":"Impact of P-glycoprotein\n(ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on\nplasma pharmacokinetics and brain accumulation of dasatinib, sorafenib,\nand sunitinib","volume":"346","author":"Tang","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026090221451685500_cit41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1023\/A:1010984110732","article-title":"Effect of mdr1a P-glycoprotein gene disruption, gender,\nand substrate concentration on brain uptake of selected compounds","volume":"18","author":"Dagenais","year":"2001","journal-title":"Pharm. Res."},{"key":"2026090221451685500_cit42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nucmedbio.2004.06.007","article-title":"Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function\nin the blood-brain barrier: kinetics and metabolism in the rat","volume":"32","author":"Luurtsema","year":"2005","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.nucmedbio.2011.10.017","article-title":"Synthesis and preclinical evaluation\nof [11C]D617, a metabolite of (R)-[11C]verapamil","volume":"39","author":"Verbeek","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2967\/jnumed.108.058453","article-title":"Human brain imaging\nand radiation dosimetry of 11C-N-desmethyl-loperamide,\na PET radiotracer to measure the function of P-glycoprotein","volume":"50","author":"Seneca","year":"2009","journal-title":"J. Nucl. Med."},{"key":"2026090221451685500_cit45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.nucmedbio.2009.12.010","article-title":"Effects\nof ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type\nand P-gp knockout mice","volume":"37","author":"Seneca","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2967\/jnumed.108.056226","article-title":"P-glycoprotein function\nat the blood-brain barrier imaged using 11C-N-desmethyl-loperamide\nin monkeys","volume":"50","author":"Liow","year":"2009","journal-title":"J. Nucl. Med."},{"key":"2026090221451685500_cit47","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.2337\/db07-1410","article-title":"Cerebral blood flow and cerebral\nedema in rats with diabetic ketoacidosis","volume":"57","author":"Yuen","year":"2008","journal-title":"Diabetes"},{"key":"2026090221451685500_cit48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/mrm.1178","article-title":"Cerebral perfusion during anesthesia with fentanyl, isoflurane, or\npentobarbital in normal rats studied by arterial spin-labeled MRI","volume":"46","author":"Hendrich","year":"2001","journal-title":"Magn. Reson. Med."},{"key":"2026090221451685500_cit49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1213\/00000539-198406000-00002","article-title":"Regional blood flow during isoflurane\nand halothane anesthesia","volume":"63","author":"Gelman","year":"1984","journal-title":"Anesth. Analg."},{"key":"2026090221451685500_cit50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.nucmedbio.2004.02.008","article-title":"Availability of N-isopropyl-p-[125I]iodoamphetamine (IMP) as a practical cerebral blood flow\n(CBF) indicator in rats","volume":"31","author":"Temma","year":"2004","journal-title":"Nucl. Med. Biol."},{"key":"2026090221451685500_cit51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1213\/00000539-198408000-00001","article-title":"Contrasting effects\nof halothane, isoflurane, and enflurane on in vivo drug metabolism\nin the rat","volume":"63","author":"Wood","year":"1984","journal-title":"Anesth. Analg."},{"key":"2026090221451685500_cit52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/bja\/60.7.791","article-title":"Comparison of the effects of isoflurane\nor fentanyl-nitrous oxide anaesthesia on propranolol disposition in\ndogs","volume":"60","author":"Reilly","year":"1988","journal-title":"Br. J. Anaesth."},{"key":"2026090221451685500_cit53","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2967\/jnumed.113.130161","article-title":"Activity of P-glycoprotein, a beta-amyloid transporter\nat the blood-brain barrier, is compromised in patients with mild Alzheimer\ndisease","volume":"55","author":"Deo","year":"2014","journal-title":"J. Nucl. Med."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5b00168","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/12\/9\/3214\/67090408\/acs.molpharmaceut.5b00168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/12\/9\/3214\/67090408\/acs.molpharmaceut.5b00168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:05Z","timestamp":1788400145000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/12\/9\/3214\/1379577\/Factors-Governing-P-Glycoprotein-Mediated-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,22]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,7,22]]},"published-print":{"date-parts":[[2015,9,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00168","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,22]]}}}